Goldman Sachs likens obesity drugs to early Amazon and Apple...

Goldman Sachs likens obesity drugs to early Amazon and Apple, suggesting they may expand into unanticipated areas. With potential customers exceeding 100 million in the U.S., the market for these treatments is vast. Investors are urged to consider Lilly call options expiring in January 2025.